Targeting airway remodelling in asthma: The how, what and where?
Conflict of interest statement: Between 2006–11, GK received travel sponsorships from Boehringer Ingelheim (BI), Pfizer, AstraZeneca (AZ) and GlaxoSmithKline (GSK) to attend national and international meetings including Pharmaceutical Industry sponsored and independent Society Scientific meetings. A proportion of GK's research work is conducted at the Woolcock Institute of Medical Research, which receives unrestricted grants from BI, AZ and GSK, and which has consultancy agreements with Pfizer, BI, AZ and GSK. GK provides consultancy services related to asthma and COPD, which include sitting on advisory boards and speaking at local and national meetings, and his research group receives a proportion of the grants and monies that arise from those companies. GK's research group is supported from competitive grants arising from local research foundations, the National Health and Medical Research Council of Australia, Cooperative Research Centre for Asthma and Airways and The Australian Lung Foundation.
No abstract is available for this article.